Close Menu

NEW YORK – Based on new Phase III clinical trial data, some oncologists suspect it may be a matter of time before checkpoint immunotherapy is routinely included in neoadjuvant and first-line adjuvant treatments for early-stage triple-negative breast cancer (TNBC) — an aggressive breast cancer marked by tumors with low estrogen, progesterone, and HER2 expression.

"Very likely, these agents will be used in early triple-negative breast cancer," said Javier Cortes, a medical oncologist at the Vall d'Hebron Institute of Oncology in Barcelona, who co-authored the trial.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Genomics is a key element in the potential of precision medicine to transform oncology. 


This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Sponsored by

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.